Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing
Shares of Cingulate Inc. blasted 226.3% higher in premarket trading Thursday after the biopharmaceutical company disclosed that the delisting of its stock...